Literature DB >> 21289145

Performance of the Abbott RealTime HIV-1 viral load assay is not impacted by integrase inhibitor resistance-associated mutations.

Thomas P Young1, Gavin Cloherty, Signe Fransen, Laura Napolitano, Priscilla Swanson, Christine Herman, Neil T Parkin, John Hackett.   

Abstract

The Abbott RealTime HIV-1 viral load assay uses primers and probes targeted to integrase, which is also the target of integrase inhibitors such as raltegravir. Viral loads of 42 raltegravir-susceptible and 40 raltegravir-resistant specimens were determined using RealTime HIV-1 and Roche Monitor (v1.5). The differences in viral load measurements between assays were comparable in the two groups, demonstrating that the RealTime HIV-1 assay can tolerate raltegravir-selected mutations.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21289145      PMCID： PMC3122809          DOI： 10.1128/JCM.02253-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  15 in total

1.  Increased levels of HIV RNA detected in samples with viral loads close to the detection limit collected in Plasma Preparation Tubes (PPT).

Authors:  Brigitte P Griffith; Donald R Mayo
Journal:  J Clin Virol       Date:  2005-10-25       Impact factor: 3.168

2.  Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from Brazil.

Authors:  Priscilla Swanson; Shihai Huang; Vera Holzmayer; Pierre Bodelle; Julie Yamaguchi; Catherine Brennan; Roberto Badaro; Carlos Brites; Klara Abravaya; Sushil G Devare; John Hackett
Journal:  J Virol Methods       Date:  2006-02-28       Impact factor: 2.014

3.  A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples.

Authors:  Ning Tang; Shihai Huang; John Salituro; Wai-Bing Mak; Gavin Cloherty; Julie Johanson; Yu Hong Li; George Schneider; John Robinson; John Hackett; Priscilla Swanson; Klara Abravaya
Journal:  J Virol Methods       Date:  2007-08-17       Impact factor: 2.014

Review 4.  Integrase inhibitors in the treatment of HIV-1 infection.

Authors:  William G Powderly
Journal:  J Antimicrob Chemother       Date:  2010-09-18       Impact factor: 5.790

5.  The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons.

Authors:  Michael Giordano; Thomas Kelleher; Richard J Colonno; Adriano Lazzarin; Kathleen Squires
Journal:  J Clin Virol       Date:  2006-04       Impact factor: 3.168

6.  Transient viremia in HIV-infected patients and use of plasma preparation tubes.

Authors:  Valentina Stosor; Frank J Palella; Baiba Berzins; Michele Till; Angel Leake; Joan S Chmiel; Robert L Murphy
Journal:  Clin Infect Dis       Date:  2005-10-21       Impact factor: 9.079

7.  Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.

Authors:  Signe Fransen; Soumi Gupta; Robert Danovich; Daria Hazuda; Michael Miller; Marc Witmer; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

8.  Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.

Authors:  Max Lataillade; Jennifer Chiarella; Michael J Kozal
Journal:  Antivir Ther       Date:  2007

9.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

10.  Resistance to integrase inhibitors.

Authors:  Mathieu Métifiot; Christophe Marchand; Kasthuraiah Maddali; Yves Pommier
Journal:  Viruses       Date:  2010-06-25       Impact factor: 5.048
View more
  1 in total

Review 1.  Systematic review of the performance of HIV viral load technologies on plasma samples.

Authors:  Kimberly A Sollis; Pieter W Smit; Susan Fiscus; Nathan Ford; Marco Vitoria; Shaffiq Essajee; David Barnett; Ben Cheng; Suzanne M Crowe; Thomas Denny; Alan Landay; Wendy Stevens; Vincent Habiyambere; Jos Perrins; Rosanna W Peeling
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.